Object and Purpose of the Sample Clauses

Object and Purpose of the. Contract The subject of this Contract is a performance of the Clinical Trial titled “A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS,” Protocol No. MN43964, hereinafter referred to as the ‘Study’. 2. The objective of this Contract is to stipulate conditions for conducting the Study and to stipulate rights and obligations of Contract parties regarding conduct of the Study and processing its results. 3. IQVIA and Sponsor hereby appoint the Institution and Principal Investigator to conduct the Study, and the Institution agrees to ensure that the Institution and the Institution’s employees, agents, and staff will conduct the Study in accordance with the Protocol (as may be amended by Sponsor), the terms of this Contract and any other the attachments hereto, which all are incorporated by reference herein (the “Contract”), good clinical practice, and all applicable laws and regulations.

Object and Purpose of the. Contract The subject of this Contract is a performance of the Clinical Trial titled “AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR X. XXXXXXXX‑XX XXXXX LTDSPONSORED ATEZOLIZUMAB STUDY”, Protocol No. BO39633, hereinafter referred to as the ‘Study’. 2. The objective of this Contract is to stipulate conditions for conducting the Study and to stipulate rights and obligations of Contract parties regarding conduct of the Study and processing its results.

Object and Purpose of the. Contract“, paragraph 1., is hereby deleted and replaced with the following: I. Object and Purpose of the Contract 1. The subject of this Contract is a performance of the Clinical Trial titled “A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS MONOTHERAPY AND IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH TÍMTO SE POTVRZUJE: VZHLEDEM K TOMU, že Smluvní výzkumná organizace, Poskytovatel zdravotních služeb a Zadavatel jsou smluvními stranami smlouvy s názvem Smlouva o klinickém hodnocení, Protokol č. WO30070, „MULTICENTRICKÉ, RANDOMIZOVANÉ, XXXXXXXX XXXXXXXXXXXX, XXXXXXX XXXXXXXXX XXXXXXXX HODNOCENÍ FÁZE III XXXXXXXXXX XXXXXXXXXXXX (XXXXXXXXXX XXXXX XXXXXXX XX-X0) V KOMBINACI S GEMCITABINEM A KARBOPLATINOU V POROVNÁNÍ SE SAMOTNÝM GEMCITABINEM A KARBOPLATINOU U PACIENTŮ S DOSUD NELÉČENÝM MÍSTNĚ POKROČILÝM NEBO METASTÁZUJÍCÍM UROTELIÁLNÍM KARCINOMEM, KTEŘÍ NEJSOU ZPŮSOBILÍ K LÉČBĚ NA BÁZI CISPLATINY“ účinné k 9. červnu 2016 (xxxx xxx „Smlouva”), a že si smluvní strany přejí tuto Smlouvu pozměnit, VZHLEDEM K TOMU, že se strany dohodly na změně této Smlouvy s ohledem na změny v Protokol Amendmentu č. 3 s datem 21. září 2016 a Protokol Amendmentu č. 4 s datem 27. června 2017; NYNÍ, Z TOHOTO DŮVODU, po xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx v této Smlouvě a dalších řádných a hodnotných protiplnění, jejichž přijetí a dostatečnost je tímto potvrzena, se strany dohodly na změně Smlouvy takto: Článek I. Smluvní strany se dohodly, že z důvodu změny názvu Protokolu se článek I. „Předmět a účel Smlouvy“, odstavec 1., tímto ruší a nahrazuje následujícím zněním: I. Předmět a účel Smlouvy 1. Předmětem této Smlouvy je provedení klinického hodnocení: „MULTICENTRICKÉ, RANDOMIZOVANÉ, PLACEBEM KONTROLOVANÉ KLINICKÉ HODNOCENÍ FÁZE III ZKOUMAJÍCÍ ATEZOLIZUMAB (PROTILÁTKU PROTI LIGANDU PD-L1) JAKO MONOTERAPII A V KOMBINACI S CHEMOTERAPIÍ NA BÁZI PLATINY U

Object and Purpose of the. Contract Predmet a cieľ zmluvy 1. The subject of this Contract is the Clinical Trial of 1. Predmetom tejto zmluvy je klinické skúšanie the human drug titled: “A Ph II/III seamless, multi- humánneho liečiva s názvom: „Multicentrické, center, randomized, double blind, placebo-controlled randomizované, dvojito zaslepené, placebom study of the reduction in signs and symptoms and kontrolované klinické skúšanie, spojenej fázy II a III, inhibition of structural damage during treatment with sledujúce vplyv liečby tocilizumabom na redukciu tocilizumab versus placebo in patient with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naïve to TNF antagonist therapy”, Protocol number: NA22823, hereinafter referred to as the ‘Study’ and ‘Protocol’. prejavov a príznakov a na spomalenie štrukturálneho poškodenia u pacientov s akylozujúcou spondylitídou, neodpovedajúcich na liečbu nesteroidnými protizápalovými liekmi a doteraz neliečených antagonistami TNF“, číslo protokolu: NA22823, ďalej iba “klinické skúšanie” a „protokol“. 2. The objective of this Contract is to stipulate conditions for conducting the Study and to stipulate rights and obligations of Contract parties regarding conduct of the Study and processing its results.

Object and Purpose of the. Contract The subject of this Contract is a performance of the Clinical Trial titled „A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY”, Protocol No. WO39210, hereinafter referred to as the ‘Study’. 2. The objective of this Contract is to stipulate conditions for conducting the Study and to stipulate rights and obligations of Contract parties regarding conduct of the Study and processing its results. 3. Contractual research organization and Sponsor hereby appoint the Health Service Provider and Principal Investigator to conduct the Study, and the Health Service Provider agrees to ensure that the Health Service Provider and the Health Service Provider’s employees, agents, and staff will conduct the Study in accordance with the Protocol (as may be amended by Sponsor), the terms of this Contract and any other the attachments hereto, which all are incorporated by reference herein (the “Contract”), good clinical practice, and all applicable laws and regulations.

Object and Purpose of the. Contract Predmet a cieľ zmluvy 1. The subject of this Contract is the Clinical Trial of 1. Predmetom tejto zmluvy je klinické skúšanie the human drug titled: “A randomized, double-blind, humánneho liečiva s názvom: „Randomizované, parallel-group placebo-controlled study of the safety dvojito zaslepené, placebom kontrolované skúšanie and reduction of signs and symptoms during v paralelných skupinách, sledujúce vplyv liečby treatment with tocilizumab (TCZ) versus placebo in tocilizumabom na bezpečnosť a na redukciu prejavov 2. The objective of this Contract is to stipulate conditions for conducting the Study and to stipulate rights and obligations of Contract parties regarding conduct of the Study and processing its results. a príznakov u pacientov s ankylozujúcou spondylitídou, ktorí nedostatočne odpovedajú na predchádzajúcu liečbu antagonistami TNF“, číslo protokolu: WA22908, ďalej iba “klinické skúšanie” a „protokol“.

Related to Object and Purpose of the

Scope and Purpose 1.01 This document is intended to set out general guidelines and principles regarding child welfare sector integrations during the term of this agreement which are mandated by the Ministry and for which local Human Resources Adjustment Plans (HRAP) are required to be negotiated. Subject to the following terms, these principles will serve as the framework for the treatment of bargaining unit employees and will apply to subsequent negotiations with unions, as may be required, as part of an integration arising within the context of the Ontario Labour Relations Act (OLRA) or PSLRTA, whichever is applicable. 1.02 Employees who may be impacted by an integration are valued and are to be treated fairly and respectfully. The parties agree that they will make reasonable efforts to reduce any negative affect on employees as a result of an integration in accordance with the following.
Object and Scope of the Agreement The competent authorities of the Contracting Parties shall provide assistance through exchange of information that is foreseeably relevant to the administration and enforcement of the domestic laws of the Contracting Parties concerning taxes covered by this Agreement. Such information shall include information that is foreseeably relevant to the determination, assessment and collection of such taxes, the recovery and enforcement of tax claims, or the investigation or prosecution of tax matters. Information shall be exchanged in accordance with the provisions of this Agreement and shall be treated as confidential in the manner provided in Article 8. The rights and safeguards secured to persons by the laws or administrative practice of the requested Party remain applicable to the extent that they do not unduly prevent or delay effective exchange of information.
INTENT AND PURPOSE The Employer and the Union each represent that the purpose and the intent of this Agreement is to promote cooperation and harmony, to recognize mutual interests, to provide a channel through which information and problems may be transmitted from one to the other, to formulate rules to govern the relationship between the Union and the Employer, to promote efficiency and service, and to set forth herein the basic agreements covering rates of pay, hours of work, and conditions of employment.
Introduction and Purpose Introduction • Neighbourhood Development Plans • Neighbourhood Development Orders
Parties and Purpose This agreement (the “Agreement”) is entered by and between certain portfolios and classes thereof, specified below and in Schedule C, of Franklin Xxxxxxxxx Variable Insurance Products Trust, an open-end management investment company organized as a statutory trust under Delaware law (the “Trust”), Franklin/Xxxxxxxxx Distributors, Inc., a California corporation which is the principal underwriter for the Trust (the “Underwriter,” and together with the Trust, “we” or “us”), the insurance company identified on Schedule A (together “you”) and your distributor, on your own behalf and on behalf of each segregated asset account maintained by you that is listed on Schedule B, as that schedule may be amended from time to time (“Account” or “Accounts”). The purpose of this Agreement is to entitle you, on behalf of the Accounts, to purchase the shares, and classes of shares, of portfolios of the Trust (“Portfolios”) that are identified on Schedule C, consistent with the terms of the prospectuses of the Portfolios, solely for the purpose of funding benefits of your variable life insurance policies or variable annuity contracts (“Contracts”) that are identified on Schedule D. This Agreement does not authorize any other purchases or redemptions of shares of the Trust.
Formation and Purpose Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC, and, optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a Committee (other than the JSC and the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the Parties will thereafter promptly create the so-deferred Committee. Joint Steering Committee (“JSC”) Establish projects for the Bacteriophage Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans (except for decisions of the IPC). The JSC shall establish budgets not less than on a quarterly basis. Chemistry, Manufacturing and Controls Committee (“CMCC”) Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Bacteriophage Program. Regulatory Committee (“RC”) Review and approve all research and development plans and projects, including clinical projects, associated with any necessary regulatory approvals, all associated publications, and all regulatory filings and correspondence relating to gaining regulatory approval for new Ampliphi Products under the Bacteriophage Program; and review and approve itemized budgets with respect to the foregoing. Commercialization Committee (“CC”) Establish project plans and review and approve activities and budgets for Commercialization activities under the Bacteriophage Program. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Intellectual Property Committee (“IPC”) Evaluate all intellectual property issues in connection with the Bacteriophage Program; review and approve itemized budgets with respect to the foregoing.
Purpose of Evaluation 10.1.1 It is recognized that a system of evaluation is essential to assist Unit Members in developing competency and realizing their potential. It is further recognized that information gathered through such a system will enable decisions that measure a Unit Member’s performance in a just and equitable manner. 10.1.2 The evaluation procedure is a cooperative process designed to: a. Promote the achievement of goals and objectives of the County Office and its programs through the assessment and evaluation of the staff that perform within that program; b. Provide a formal method of recognizing staff achievement and growth; c. Identify abilities and specific indicators most critical to support job performance; d. Develop suggestions and direction regarding desired performance and improvement based on standards for like positions; e. Increase the employee’s understanding of performance from the supervisor’s viewpoint; and f. Provide a process of two-way communication to evaluate job performance.
Purpose of Use The Executive agrees that he will use Confidential Information only for purposes authorized or directed by the Company.
Purpose of Company The purpose of the Company is to engage in any lawful act or activity for which limited liability companies may be formed under the Act and to engage in any and all activities necessary or incidental thereto.
PURPOSE OF THIS AGREEMENT The purpose of this Agreement is to - 2.1 comply with the provisions of Section 57(1)(b), (4A), (4B) and (5) of the Systems Act as well as the employment contract entered into between the parties; 2.2 specify objectives and targets defined and agreed with the Employee and to communicate to the Employee the Employer’s expectations of the Employee’s performance and accountabilities in alignment with the Integrated Development Plan, Service Delivery and Budget Implementation Plan (SDBIP) and the Budget of the Employer; 2.3 specify accountabilities as set out in a performance plan, which forms an annexure to the performance agreement; 2.4 monitor and measure performance against set targeted outputs; 2.5 use the performance agreement as the basis for assessing whether the Employee has met the performance expectations applicable to his or her job; 2.6 in the event of outstanding performance, to appropriately reward the Employee; and 2.7 give effect to the Employer’s commitment to a performance-orientated relationship with its

Object and Purpose of the Sample Clauses

Filter & Search

Related Clauses

Related to Object and Purpose of the